Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

130.55 +1.11 (+0.86%)
Official Closing Price Updated: 4:15 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
51 52 Next >
7 Stocks That AI Says Will Make You a Millionaire by 2025
These seven millionaire-maker stocks are changing hands at deeply undervalued levels. As their growth re-accelerates, so will your portfolio. 
Via InvestorPlace
Why Isn't Biogen Stock Soaring After This Major FDA Approval?
Is the stock a good contrarian buy? 
Via The Motley Fool
P/E Ratio Insights for Biogen
Via Benzinga
Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi
Biogen's shares decline after approval of Alzheimer's treatment Leqembi, which modestly slows cognitive decline. Analysts see hurdles to the rollout. 
Via MarketBeat
Exposures Product Safety
Biogen Just Reached a Big Milestone. Why Isn't the Stock Rising?
Biogen shares are little changed year to date. 
Via The Motley Fool
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $4,900 Today
Via Benzinga
What 29 Analyst Ratings Have To Say About Biogen
Via Benzinga
What's Going On With Biogen Stock Thursday
Biogen Inc (NASDAQ: BIIB) shares were flat in Thursday's after-hours session after falling marginally by 0.31% to $284.99 during  
Via Benzinga
How Is The Market Feeling About Biogen?
Via Benzinga
Mixed Jobs Data; Fed Governors Want More Interest Rate Hikes; US, China Spat Rattles Semiconductor Sector: The Week In The Markets
Via Benzinga
Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts
The FDA approved a supplemental marketing application for Biogen Inc (NASDAQ: BIIB)-Eisai Co Ltd (OTC: ESALY) supporting the traditional approval of Leqembi (lecanemab-irmb), making it the first and... 
Via Benzinga
FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline
The FDA fully approved Biogen Inc.’s (NASDAQ: BIIB) Alzheimer’s treatment Leqembi on Thursday, becoming the first Alzheimer’s antibody treatment to reach full approval. 
Via Benzinga
Stock Market Rally Pulls Back As Yields Jump; Tesla, Meta In Focus: Weekly Review
Automakers rallied on sales while Meta's Threads had a big launch. 
Via Investor's Business Daily
A Look Into Biogen Inc's Price Over Earnings
Via Benzinga
$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today
Via Benzinga
FSLR Stock Alert: The $1 Billion Reason First Solar Is Up Today
First Solar (FSLR) stock is rising higher on Friday after the solar energy company announced a $1 billion revolving credit facility. 
Via InvestorPlace
Why Is Alibaba (BABA) Stock Up Today?
Alibaba (BABA) stock is on the rise Friday as investors react to a few pieces of news considering the Chinese e-commerce giant. 
Via InvestorPlace
BIIB Stock Alert: What to Know as FDA Approves Biogen’s Alzheimer’s Drug
Biogen (BIIB) stock is in the news Friday after the pharmaceutical company got approval from the FDA for its Alzheimer's drug. 
Via InvestorPlace
Stock Futures Dip As Traders Eye Friday Jobs Report: Analyst Says Q3 Returns Hinge More On This Catalyst Than Fed Move
Via Benzinga
Top 5 Trending Stocks: Prestige Wealth's IPO, Rivian's Lawsuit, Meta's New Platform, Tesla's Dip, And Biogen's FDA Approval
Via Benzinga
FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
3 Biotech Stocks to Make Your ‘Get Rich’ Dreams Come True
These high return biotech stocks offer tremendous upside ahead and are likely to soar on the back of several growth drivers 
Via InvestorPlace
Biogen's Make-Or-Break Moment Is Here In Alzheimer's Treatment
The FDA is expected to announce Thursday whether it has approved or rejected Biogen's Alzheimer's drug. 
Via Investor's Business Daily
Biogen Reports New Spinraza Data In Atrophy Patients After Incomplete Response To Novartis' Treatment
Biogen Inc (NASDAQ: BIIB) announced new Spinraza (nusinersen) data that were presented at the SMA Research & Clinical Care Meeting  
Via Benzinga
New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
From Biogen Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Amgen Inc. Dividend Stock Analysis
The company has paid a cash dividend to shareholders every year since 2011 and has increased its dividend payments for 13 consecutive years. 
Via Talk Markets
Is This a Sign That Biogen's Leqembi Could Obtain FDA Approval Next Month?
The catalyst many Biogen investors have been waiting for may soon arrive. 
Via The Motley Fool
Alleged Industrial Espionage Makes an Interesting Story
We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment. 
Via The Motley Fool
5 Biotech Stocks That Could Soar Thanks To These Disruptive Healthcare Technologies
Via Benzinga
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
51 52 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS